Whereas patients with IDH-wildtype GBM show a low median rate of survival of 14 to 16 months, patients with IDH-mutant GBM exhibit prolonged survival (median survival up to 31 months) and slower progression (1, 2). Here, IDH1 is linked to glioblastoma.